A 2-dose regimen of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 was authorized in December 2020 based on reported 94.8% efficacy.
1 Although an association between vaccination and a reduction in symptomatic disease has been well described, an association with asymptomatic infection remains unclear.
2,3